melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Seven human tumour xenografts were analysed in nude mice; five tumours (KEsC-2, oesophageal carcinoma; FA-6, pancreatic carcinoma; SEKI, melanoma; Lu-65A and Lu-61, lung carcinomas) were associated with hypercalcaemia and two tumours (MIA PaCa-2, pancreatic carcinoma; PLC/PRF/5, hepatocellular carcinoma) with normocalcaemia.
|
1997102 |
1991 |
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Northern blot analysis confirmed MIA mRNA expression in nonmetastasizing melanoma cell lines and in melanoma metastasis lesions, while expression was absent in highly metastasizing cell lines and pretumor stages.
|
8521420 |
1995 |
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To investigate mechanisms mediating this melanoma-associated expression pattern, we analyzed the promoter activity of the 1.3-kilobase genomic sequences located 5'-upstream of the MIA gene.
|
8550608 |
1996 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The protein from human melanoma cell lines and tumors is called melanoma inhibitory activity (MIA) (Blesch et al.[1994] Cancer Res.
|
9097023 |
1997 |
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Eleven (84.6%) of 13 PBMC samples from patients with metastasized melanoma and clinically evident disease without treatment were MIA mRNA-positive in contrast to only 19 (25.7%) of 74 samples isolated from patients in stage IV with metastasis during chemotherapy.
|
10353744 |
1999 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Melanoma inhibitory activity (MIA) is one such melanoma-specific candidate gene.
|
10576666 |
1999 |
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Characterization of a transcription factor binding site, specifically activating MIA transcription in melanoma.
|
10886506 |
2000 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To provide direct evidence that MIA plays a role in metastasis of malignant melanomas, A-mel 3 hamster melanoma cells were transfected with sense- and antisense rhMIA cDNA and analysed subsequently for changes in their tumorigenic and metastatic potential.
|
11027436 |
2000 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although MIA discriminated melanoma from nonmelanoma at least as well as tyrosinase, no single mRNA marker had accuracy greater than 71%, raising potential concern about application of these particular mRNA markers to the minimal disease setting.HUM PATHOL 31:1381-1388.
|
11112213 |
2000 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Melanoma inhibitory activity (MIA) protein is a clinically valuable marker in patients with malignant melanoma, as enhanced values diagnose metastatic melanoma stages III and IV.
|
11157741 |
2001 |
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We prepared organotypic brain slice cultures from newborn rats to investigate the invasive behavior of human brain tumors using glial tumor cell lines (U-87MG, U-373MG, U-251MG, and SF-126) and of non-CNS tumors using cell lines; HT-1080 (human malignant fibrosarcoma), RFRF (human lung carcinoma), MIA-PICA (human pancreatic carcinoma), and Colo38 (human malignant melanoma).
|
11251166 |
2001 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A number of studies from different laboratories evaluated MIA as a highly specific and sensitive marker, clinically useful for follow-up and therapy-monitoring of patients with malignant melanomas.
|
11813878 |
2002 |
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
All melanomas tested (n = 19) expressed high levels of MIA mRNA and protein.
|
12014625 |
2002 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cloning and characterization of the expression pattern of a novel splice product MIA (splice) of malignant melanoma-derived growth-inhibiting activity (MIA/CD-RAP) [corrected].
|
12230496 |
2002 |
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Down-regulation of COOH-terminal binding protein expression in malignant melanomas leads to induction of MIA expression.
|
12384563 |
2002 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The melanoma inhibitory activity (MIA) protein is a clinically valuable marker in patients with malignant melanoma as enhanced values diagnose metastatic melanoma stages III and IV.
|
12592021 |
2003 |
melanoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
In summary, our study proves HMG1 and p65 to be important factors in MIA regulation and melanoma progression.
|
12665595 |
2003 |
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our data indicate that the enhancer/tyrosinase and enhancer/MIA promoter constructs but not the viral promoter constructs can provide a valuable tool for selective suicide gene expression in melanoma.
|
14714561 |
2003 |
melanoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
Melanoma inhibitory activity, secreted by melanoma cells, is known to inhibit tumour cell attachment to the extracellular matrix enhancing their invasive potential.
|
15057037 |
2004 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MIA (melanoma inhibitory activity) promoter mediated tissue-specific suicide gene therapy of malignant melanoma.
|
15118759 |
2004 |
melanoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
The goal of this study was to determine the effect of ultraviolet radiation (UVR), activating ras mutation, or loss of p53 function on MIA expression and release from melanoma cells.
|
15201995 |
2004 |
melanoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
These results suggest that expression of MIA promotes melanoma progression by inducing further melanoma-associated genes.
|
15208686 |
2004 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genes MIA (melanoma inhibitory activity) and PLA2G2A (phospholipase A2, group IIA) show the highest specificity as cardiac myxoma markers, since they have more than 10-fold higher RNA level in cardiac myxomas than in any one of 15 normal tissues tested.
|
15350845 |
2004 |
melanoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Melanoma inhibitory activity (MIA) is an 11 kD protein secreted by malignant melanomas.
|
15386421 |
2005 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Twenty-seven of 36 serum GPC3-positive patients were negative for both serum 5-S-cysteinyldopa and melanoma-inhibitory activity, well-known tumor markers for melanoma.
|
15475451 |
2004 |